All In MedTech

Device Trial Radar · NCT04508335

Feasibility Study of the Reia Vaginal Pessary

Assessment of Effectiveness and Safety of a Novel Pessary for the Non-Surgical Treatment of Pelvic Organ Prolapse

Last checked: Nov 20, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

78

Actual

Start

Nov 21, 2021

Primary completion

Jun 16, 2023

Study completion Jun 16, 2023

Sponsor

Lead sponsor
Reia, LLCNot on our public-company list
Sponsor type
Industry
First posted
Aug 11, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to obtain preliminary data on the effectiveness, safety, function, comfort, and patient satisfaction with a novel vaginal pessary design for the use in women who suffer from symptoms of pelvic organ prolapse (POP) and have already opted for non-surgical management. Recruited patients will have Stage II POP or greater and will be current users of a Gellhorn or ring style pessary. Following enrollment, each subject will enter a 1-month wash out period in which they will continue using their current pessary so that baseline subjective and objective data can be collected. They will then be fit with a study pessary and enter a 3-month treatment phase. Comparative, subjective, and objective data will be collected at the conclusion of the study.

Conditions

  • Pelvic Organ Prolapse

Interventions

  • Reia Vaginal PessaryDevice

    Reia Vaginal Pessary

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pelvic Floor Distress Inventory-20 (PFDI-20)Time frame: At enrollment [Week 0] and post treatment [Week 16]
  2. Adverse EventsTime frame: Throughout study, an average of 16 weeks - AEs may be reported at any time

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Boston Urogynecology Associates

    Cambridge, Massachusetts

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.